Table of Contents

company-logo

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics Dividend Announcement

• Black Diamond Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Black Diamond Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Black Diamond Therapeutics Dividend History

Black Diamond Therapeutics Dividend Yield

Black Diamond Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Black Diamond Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Black Diamond Therapeutics Financial Ratios

P/E ratio-2.61
PEG ratio0.03
P/B ratio1.96
ROE-68.08%
Payout ratio0.00%
Current ratio5.55
Quick ratio5.55
Cash Ratio1.13

Black Diamond Therapeutics Dividend FAQ

Does Black Diamond Therapeutics stock pay dividends?
Black Diamond Therapeutics does not currently pay dividends to its shareholders.
Has Black Diamond Therapeutics ever paid a dividend?
No, Black Diamond Therapeutics has no a history of paying dividends to its shareholders. Black Diamond Therapeutics is not known for its dividend payments.
Why doesn't Black Diamond Therapeutics pay dividends?
There are several potential reasons why Black Diamond Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Black Diamond Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Black Diamond Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Black Diamond Therapeutics a dividend aristocrat?
Black Diamond Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Black Diamond Therapeutics a dividend king?
Black Diamond Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Black Diamond Therapeutics a dividend stock?
No, Black Diamond Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Black Diamond Therapeutics stocks?
To buy Black Diamond Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Black Diamond Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.